IL23A and inflammatory bowel disease: For instance, mAbs targeting cytokines such as TNF-α, IL-17, or IL-23 have significantly improved the management of autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD).2 Small molecule inhibitors have also shown efficacy in many conditions.